Feb. 25, 2025 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals ... Alkeus' breakthrough-designated lead candidate, gildeuretinol acetate (ALK-001), is a new molecular entity currently being evaluated ...

Feb. 25, 2025 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals ... Alkeus’ breakthrough-designated lead candidate, gildeuretinol acetate (ALK-001), is a new molecular entity currently being evaluated ...

Preeminent retinal disease expert panel to support Alkeus' development programs and science CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals ... gildeuretinol acetate ...

CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases ...

ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has launched Galzin ® (zinc acetate) capsules.

The following adverse reactions associated with the use of zinc acetate were identified from postmarketing reports. Because these reactions were reported voluntarily from a population of uncertain ...